Fulvestrant-fig-1 (Fulvestrant Fig 1)
Fulvestrant Injection
Product Images NDC 68001-626
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 17 technical images submitted to the FDA as part of the official labeling for Fulvestrant (NDC 68001-626). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Bluepoint Laboratories., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Fulvestrant-fig-10 (Fulvestrant Fig 10)
This document provides a comparative analysis of two treatment groups: Fulvestrant + palbociclib and Fulvestrant + placebo. The table displays the overall survival probabilities of the patients in both groups over a duration of 54 months. The data includes the number of patients at risk in each group at different time points.*
Fulvestrant-fig-11 (Fulvestrant Fig 11)
This is a comparison of Fulvestrant plus Abemaciclib versus Fulvestrant plus Placebo in terms of Progression-Free Survival Probability over a 30-month period. The data includes the number of patients at risk at different time points, showing the progression of the disease in both groups. The study involved 446 patients in the Fulvestrant plus Abemaciclib group and 223 patients in the Fulvestrant plus Placebo group.*
Fulvestrant-fig-12 (Fulvestrant Fig 12)
This is a comparison of two treatments: Fulvestrant plus Abemaciclib (446 patients) and Fulvestrant plus Placebo (223 patients) over a span of time (in months) with the number of patients at risk shown at each time point for each treatment group.*
Fulvestrant-fig-13 (Fulvestrant Fig 13)
This is a graph showing "Event-free probability (%)" over time (months) for two different treatment groups: Fulvestrant-Ribociclib (N = 484) and Fulvestrant+Placebo (N = 242). The graph provides information on the number of patients at risk at different time points.*
Fulvestrant-fig-14 (Fulvestrant Fig 14)
This text is showing censoring times for two groups in a study: one group receiving Fulvestrant+Fibociclib with 484 patients and the other receiving Fulvestrant+Placebo with 242 patients. The event-free probability is graphically represented over time (in months) for both groups, along with the number of patients still at risk at each time point. This data can be used to analyze the effectiveness and outcomes of the treatments being compared.*
Fulvestrant-fig-2 (Fulvestrant Fig 2)
Fulvestrant-fig-3 (Fulvestrant Fig 3)
Fulvestrant-fig-4 (Fulvestrant Fig 4)
Fulvestrant-fig-5 (Fulvestrant Fig 5)
Fulvestrant-fig-6 (Fulvestrant Fig 6)
This data provides the proportion of patients who are progression-free over time when treated with different doses of Fulvestrant (250mg and 500mg). The graph depicts Progression-Free Survival in the ITT population over a period of 27 months. It shows the number of patients at risk at different time points, illustrating a comparison between the two doses.*
Fulvestrant-fig-7 (Fulvestrant Fig 7)
This text provides data on the survival rates of patients taking different dosages of Fulvestrant (500mg and 250mg) over a period of 80 months. The graph shows the proportion of patients alive at various time points. The study concludes that the difference in survival rates between the two dosages is not statistically significant. No adjustments were made for multiplicity in the analysis.*
Fulvestrant-fig-8 (Fulvestrant Fig 8)
Fulvestrant-fig-9 (Fulvestrant Fig 9)
This is a comparison study between Fulvestrant + Palbociclib and Fulvestrant + Placebo in terms of Progression-Free Survival Probability over time. The chart displays the number of patients at risk for each treatment group at different time points in months. The data indicates a higher number of patients for the Fulvestrant + Palbociclib group compared to the Fulvestrant + Placebo group.*
Fulvestrant Carton 250 mg (Fulvestrant Spl Carton)
Description: This text provides details about Fulvestrant Injection, which comes in 250 mg/5 mL prefilled syringes for intramuscular use only. The medication must be refrigerated at 2-8°C and protected from light. Each box contains 2 single-dose prefilled syringes. It is important to administer both syringes to achieve a 500 mg dose.*
Fulvestrant Label 250 mg (Fulvestrant Spl Pfs)
This text is a label for a medication called Fulvestrant Injection, with a dosage of 250 mg/5 mL (50 mg/mL). The medication is for intramuscular use only and must be protected from light. It mentions that two single-dose prefilled syringes need to be administered to receive the 500 mg dose. The manufacturer is Alembic Pharmaceuticals Limited based in Gujarat, India. The label also includes the NDC code (68001-626-86) and a lot number (XXXXXXX). The expiration date is noted as Rev. 09/2024.*
Fulvestrant-structure (Fulvestrant Structure)
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
